CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
应对 CAR-T 细胞毒性的策略演进
英文原题：Evolving strategies for addressing CAR T-cell toxicities.
查看英文原题
Evolving strategies for addressing CAR T-cell toxicities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已从完全实验性概念发展为多种治疗方法，目前有6种CAR-T 产品获得美国食品药品监督管理局（FDA）批准，用于治疗不同血液系统恶性肿瘤。然而，CAR-T 疗法虽有效，也伴随需要及时、审慎干预的副作用。本综述讨论迄今CAR-T 细胞最常见毒性，重点介绍风险因素、预后判断、重症监护管理影响、优化患者治疗体验的方法，以及当前毒性缓解研究。随着现有和新型CAR-T 细胞疗法逐步用于临床，理解领域现状和实践标准，对于改善和管理潜在毒性至关重要。
展开英文摘要原文
The field of chimeric antigen receptor (CAR) T-cell therapy has grown from a fully experimental concept to now boasting a multitude of treatments including six FDA-approved products targeting various hematologic malignancies. Yet, along with their efficacy, these therapies come with side effects requiring timely and thoughtful interventions.
In this review, we discuss the most common toxicities associated with CAR T-cells to date, highlighting risk factors, prognostication, implications for critical care management, patient experience optimization, and ongoing work in the field of toxicity mitigation. Understanding the current state of the field and standards of practice is critical in order to improve and manage potential toxicities of both current and novel CAR T-cell therapies as they are applied in the clinic.
论文信息
- 作者
- Rankin AW、Duncan BB、Allen C、Silbert SK、Shah NN
- 第一作者单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.United States
- 通讯作者单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Nirali.Shah@nih.gov.United States
- 文献类型
- 综述 · 美国 NIH 院内研究
- 期刊
- Cancer metastasis reviews2024 Dec 15
- 原文标识
- PubMed 39674824 · DOI 10.1007/s10555-024-10227-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →